High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia

Alimentary Pharmacology and Therapeutics

Volumn 35, Issue 4, 2012, Pages 451-457

  Lindstrom L ^a   Boberg, K M ^b   Wikman, O ^c   Friis Liby, I ^d   Hultcrantz, R ^a   Prytz, H ^e   Sandberg Gertzen H ^f   Sangfelt, P ^g   Rydning, A ^h   Folvik, G ⁱ   Gangsoy Kristiansen M ^j   Danielsson, A ^k   Bergquist, Annika ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF OSLO   (Norway)

^c STOCKHOLM SÖDER HOSPITAL   (Sweden)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

^f ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^g UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^h AKERSHUS UNIVERSITY HOSPITAL   (Norway)

ⁱ HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^j Nordland Hospital   (Norway)

^k UMEÅ UNIVERSITY   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; URSODEOXYCHOLIC ACID;

ADULT; AGED; ARTICLE; CANCER PREVENTION; CANCER SURVIVAL; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MEGADOSE; ENTERITIS; FEMALE; FOLLOW UP; GASTROINTESTINAL DYSPLASIA; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; CHOLAGOGUES AND CHOLERETICS; CHOLANGITIS, SCLEROSING; COHORT STUDIES; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SWEDEN; URSODEOXYCHOLIC ACID; YOUNG ADULT;

EID: 84856029918     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04966.x     Document Type: Article

References (22)

1. Broome U, Olsson R, Loof L, et al,. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996; 38: 610-5. (Pubitemid 26111384)
2. Loftus EV Jr, Harewood GC, Loftus CG, et al,. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005; 54: 91-6. (Pubitemid 40007225)
3. Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO,. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 2002; 56: 48-54. (Pubitemid 41115048)
4. Serfaty L, De Leusse A, Rosmorduc O, et al,. Ursodeoxycholic acid therapy and the risk of colorectal adenoma in patients with primary biliary cirrhosis: an observational study. Hepatology 2003; 38: 203-9. (Pubitemid 36775812)
5. Lindberg BU, Broome U, Persson B,. Proximal colorectal dysplasia or cancer in ulcerative colitis. The impact of primary sclerosing cholangitis and sulfasalazine: results from a 20-year surveillance study. Dis Colon Rectum 2001; 44: 77-85. (Pubitemid 32105878)
6. Claessen MM, Lutgens MW, van Buuren HR, et al,. More right-sided IBD-associated colorectal cancer in patients with primary sclerosing cholangitis. Inflamm Bowel Dis 2009; 15: 1331-6.
7. Olsson R, Boberg KM, de Muckadell OS, et al,. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomised, controlled study. Gastroenterology 2005; 129: 1464-72. (Pubitemid 41597389)
8. Lindor KD,. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997; 336: 691-5.
9. Lindor KD, Kowdley KV, Luketic VA, et al,. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009; 50: 808-14.
10. Pardi DS, Loftus EV Jr, Kremers WK, Keach J, Lindor KD,. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003; 124: 889-93. (Pubitemid 36389790)
11. Tung BY, Emond MJ, Haggitt RC, et al,. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001; 134: 89-95. (Pubitemid 32096335)
12. Wolf JM, Rybicki LA, Lashner BA,. The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis. Aliment Pharmacol Ther 2005; 22: 783-8. (Pubitemid 41564357)
13. Farraye FA, Odze RD, Eaden J, et al,. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 2010; 138: 738-45.
14. Biancone L, Michetti P, Travis S, et al,. European evidence-based consensus on the management of ulcerative colitis: special situations. J Crohns Colitis 2008; 2: 63-92. (Pubitemid 351179489)
15. Torres J, Pineton de Chambrun G, Itzkowitz S, Sachar DB, Colombel J-F,. Review article: colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease. Aliment Pharmacol Ther 2011; 34: 497-508.
16. Pekow JR, Hetzel JT, Rothe JA, et al,. Outcome after surveillance of low-grade and indefinite dysplasia in patients with ulcerative colitis. Inflamm Bowel Dis 2010; 16: 1352-6.
17. Broome U, Lofberg R, Veress B, Eriksson LS,. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology 1995; 22: 1404-8.
18. Sokol H, Cosnes J, Chazouilleres O, et al,. Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis. World J Gastroenterol 2008; 14: 3497-503.
19. Alberts D, Martinez M, Hess L, et al,. Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. J Natl Cancer Inst 2005; 97: 846-53. (Pubitemid 40909127)
20. Eaton J, Silveira M, Lindor K,. High dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol 2011; 106: 1638-45.
21. Sinakos E, Marschall HU, Kowdley KV, Befeler A, Keach J, Lindor K,. Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression. Hepatology 2010; 52: 197-203.
22. Thackeray EW, Charatcharoenwitthaya P, Elfaki D, Sinakos E, Lindor KD,. Colon neoplasms develop early in the course of inflammatory bowel disease and primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2011; 9: 52-6.